

Comment: Rare Cancers Australia CEO Richard Vines



Rare Cancers Australia CEO Richard Vines says Australian GIST patients were determined to help achieve a PBS listing for a new therapy to treat the disease and their persistence has paid off with QINLOCK® (ripretinib) now reimbursed. [Click for more.](#)